Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.
